Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 trial of GC4006A in COVID-19

Next Previous
Trial Profile

Phase 1 trial of GC4006A in COVID-19

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GC 4006A (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions

Most Recent Events

  • 22 Dec 2026 According to GC Biopharma media release, the company announced today that Ministry of Food and Drug Safety (MFDS) in South Korea has approved the Investigational New Drug (IND) application for the Phase 1 clinical trial of "GC4006A", mRNA (messenger RNA) vaccine candidate for COVID-19.
  • 10 Nov 2025 New trial record
  • 22 Sep 2025 According to GC Biopharma media release, if the IND application is approved by the end of 2025 as expected, the company will initiate the first administrations in early 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top